文献速递前列腺癌

IMPACT研究中期结果:BRCA2突变携带者前列腺特异性抗原筛查证据

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
PubMed 文献 · Eur Urol · 2019-09-16

IMPACT研究评估了BRCA1/2胚系突变男性中PSA筛查的价值。经过3年筛查,BRCA2携带者前列腺癌发病率更高、诊断年龄更轻、临床显著疾病比例更高,支持对BRCA2突变男性进行系统PSA筛查。

要点

  • BRCA2携带者前列腺癌发病率显著高于非携带者(19.4 vs 12.0/1000人年)。
  • BRCA2携带者诊断年龄更轻(61 vs 64岁)且临床显著疾病比例更高(77% vs 40%)。
  • BRCA1携带者与非携带者间年龄或肿瘤特征无差异。

核心结论

  • 经过3年筛查,BRCA2突变携带者前列腺癌发病率更高、诊断年龄更轻、临床显著肿瘤更多。
  • 因此,对BRCA2突变男性应进行系统PSA筛查。
  • BRCA1突变携带者中筛查的作用需进一步随访评估。

研究设计与样本

  • 前瞻性研究纳入40-69岁BRCA1/2胚系致病突变男性及家族BRCA1/2突变阴性男性对照。
  • 共招募3027例(2932例独特个体):BRCA1携带者919例,BRCA1非携带者709例,BRCA2携带者902例,BRCA2非携带者497例。
  • 参与者接受3年PSA筛查,若PSA>3.0 ng/ml则建议前列腺活检。

主要发现

  • 3年筛查后,527例男性PSA>3.0 ng/ml,实施357例活检,诊断112例前列腺癌(BRCA1携带者31例,BRCA1非携带者19例,BRCA2携带者47例,BRCA2非携带者15例)。
  • BRCA2携带者活检依从性高于非携带者(73% vs 60%)。
  • BRCA2携带者前列腺癌发病率高于非携带者(19.4 vs 12.0/1000人年;p=0.03)。
  • BRCA2携带者诊断年龄更轻(61 vs 64岁;p=0.04),临床显著疾病比例更高(77% vs 40%;p=0.01)。
  • BRCA1携带者与非携带者间年龄或肿瘤特征无差异。

关键数值与推荐

  • PSA>3.0 ng/ml时建议前列腺活检。
  • BRCA2携带者前列腺癌发病率19.4/1000人年 vs 非携带者12.0/1000人年(p=0.03)。
  • BRCA2携带者诊断年龄61岁 vs 64岁(p=0.04)。
  • BRCA2携带者临床显著疾病比例77% vs 40%(p=0.01)。
  • 4种激肽释放酶标志物模型AUC=0.73 vs PSA单独AUC=0.65。

临床怎么用

  • 对BRCA2突变男性应提供系统PSA筛查。
  • BRCA1突变携带者的筛查作用尚需进一步随访确定。
  • 4种激肽释放酶标志物模型可能改善临床显著癌的区分。

局限性

  • 为3年筛查的中期结果,需更长期随访。
  • BRCA1突变携带者中筛查作用尚未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. DESIGN, SETTING, AND PARTICIPANTS: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. RESULTS AND LIMITATIONS: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65). CONCLUSIONS: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers. PATIENT SUMMARY: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Page EC, Bancroft EK, Brook MN, et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019. PMID: 31537406. doi:10.1016/j.eururo.2019.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。